Jeffrey Bennett, MD
Neurology · Aurora, CONPI 1245349620
Payments from drug & device makers
Across 584 payments — averaging $3205.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1.3M
- Genentech, Inc.$177K
- UCB SA$123K
- F. Hoffmann-la Roche AG$95K
- Amgen$74K
- Tanabe Pharma Corporation$54K
- plus $83K from 17 others
Across 41 payments — averaging $445.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$18K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 339 | $1,265,512 |
| Genentech, Inc. | 34 | $177,466 |
| UCB SA | 7 | $122,563 |
| F. Hoffmann-la Roche AG | 43 | $95,250 |
| Amgen(2 entities) | 81 | $73,663 |
| Tanabe Pharma Corporation | 24 | $54,014 |
| Chugai Pharmaceutical Co., Ltd. | 9 | $24,328 |
| Roche Products Limited | 9 | $20,788 |
| Genentech USA, Inc. | 12 | $10,894 |
| AbbVie | 1 | $6,600 |
| Beigene USA, Inc. | 1 | $4,805 |
| EMD Serono, Inc. | 5 | $4,289 |
| Mitsubishi Tanabe Pharma Development America, Inc. | 1 | $3,665 |
| Merck Kgaa | 1 | $2,650 |
| Hoffmann-la Roche Limited | 1 | $2,560 |
| TG Therapeutics, Inc. | 2 | $1,979 |
| UCB Biosciences Inc. | 1 | $168 |
| UCB, Inc. | 3 | $149 |
| Bristol Myers Squibb | 5 | $116 |
| Teva Pharmaceuticals USA, Inc. | 1 | $113 |
| Argenx US, Inc. | 1 | $75 |
| Sanofi | 1 | $62 |
| Novartis | 2 | $31 |
How this compares
$1,871,742 in reported general payments places this provider in the 95th percentile of 334 neurology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Aurora
- Enrique AlvarezAurora$14.3M
- Timothy VollmerAurora$2M
- Anna ShahAurora$1.4M
- John CorboyAurora$1.3M
- Amanda PiquetAurora$1.3M
- Drew KernAurora$1.2M
- Maureen LeeheyAurora$1.1M
- Thomas RagoleAurora$841K
- Denise DamekAurora$733K
- Sana AslamAurora$695K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.